Table 2.
(A) Cox proportional multivariable regression analysis for the association of histopathologic lymph-node status (pN1 vs. pN0) with dichotomous molecular marker expression in lymph nodes (molN0 vs. molN1) and established risk factors with bRFS. (B) Cox proportional multivariable regression analysis for the association of histopathologic lymph-node status (pN1 vs. pN0), continuous molecular marker expression in lymph nodes and established risk factors with bRFS.
| Variables | Category | N | Hazard ratio | 95% CI | p value | |
|---|---|---|---|---|---|---|
| A | ||||||
| Lymph-node status | pN1 vs. pN0 | 28 vs. 83 | 1.1 | 0.5–2.2 | 0.8 | |
| molN1 vs. molN0 | ||||||
| KLK2 | 55 vs. 56 | 0.3 | 0.0–1.6 | 0.15 | ||
| KLK3 | 60 vs. 51 | 4.0 | 1.1–15.2 | 0.04 | ||
| KLK4 | 57 vs. 54 | 1.4 | 0.4–4.6 | 0.6 | ||
| PSMA | 36 vs. 75 | 0.9 | 0.3–2.5 | 0.9 | ||
| TMPRSS2 | 41 vs. 70 | 5.1 | 1.4–19.0 | 0.02 | ||
| TRPM8 | 51 vs. 60 | 1.2 | 0.4–3.3 | 0.7 | ||
| Preoperative PSA level | Continuous (per 10 ng/ml increase) | 111 | 1.0 | 0.9–1.1 | 0.3 | |
| Tumor extension at RP | pT3 or pT4 vs. pT2 | 66 vs. 45 | 1.1 | 0.5–2.3 | 0.5 | |
| Gleason score at RP | 8, 9 or 10 vs. 6 or 7 | 37 vs. 74 | 0.8 | 0.4–1.5 | 0.5 | |
| B | ||||||
| Lymph-node status | pN1 vs. pN0 | 28 vs. 83 | 1.1 | 0.5–2.3 | 0.8 | |
| Molecular continuous marker expressiona | ||||||
| KLK2 | 111 | 1.4 | 0.8–2.5 | 0.3 | ||
| KLK3 | 111 | 1.1 | 0.7–2.0 | 0.6 | ||
| KLK4 | 111 | 0.8 | 0.4–1.7 | 0.5 | ||
| PSMA | 111 | 0.6 | 0.3–1.2 | 0.16 | ||
| TMPRSS2 | 111 | 2.3 | 1.0–5.2 | 0.04 | ||
| TRPM8 | 111 | 0.7 | 0.5–1.1 | 0.13 | ||
| Preoperative PSA level | Continuous (per 10 ng/ml increase) | 111 | 1.0 | 0.9–1.1 | 0.8 | |
| Tumor extension at RP | pT3 or pT4 vs. pT2 | 66 vs. 45 | 0.8 | 0.4–1.7 | 0.5 | |
| Gleason score at RP | 8, 9 or 10 vs. 6 or 7 | 37 vs. 74 | 1.0 | 0.6–1.9 | 0.9 | |
Cox proportional multivariable regression analysis for the association of lymph-node status and established risk factors with bRFS. Lymph-node status is stratified according to histopathology as well as (A) dichotomous or (B) continuous molecular marker expression in lymph nodes.
KLK2, KLK3, KLK4 Kallikrein 2, 3, and 4, PSMA prostate-specific membrane antigen, RP radical prostatectomy, TMPRSS2 transmembrane serine protease 2, TRPM8 transient receptor potential cation channel subfamily M member 8.
aMolecular continmarker expression = Log 10 (maximum marker expression in lymph nodes per patient + 1).
Bold values represent statistically significant results (p < 0.05).